Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast
NASDAQ, TSX: NVCN
VANCOUVER, March 21, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.
Conference Call & Webcast
Wednesday, March 28th @ 4:30pm Eastern Time
| Domestic: |
800-281-7973 |
| International: |
323-794-2093 |
| Passcode: |
4395026 |
| Webcast: |
|
| Replays available through April 10: |
|
| Domestic: |
844-512-2921 |
| International: |
412-317-6671 |
| Conference ID: |
4395026 |
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
SOURCE Neovasc Inc.
Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, [email protected]; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568
Share this article